With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.
Novartis AG to buy immunology specialist Calypso Biotech BV
Latest NewsCalypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.
GLP1 agonists: FDA investigates suicide risk
Latest NewsFollowing in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Latest NewsBoehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Latest NewsItalian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Roche presents restistance-breaking antibiotic
Latest NewsHoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
The future finds a new home: HAVEL LABS
Sponsored PublicationsWith HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.
Alfasigma SpA signs €170m deal with Galapagos NV
Latest NewsFollowing its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.
Next European Biotechnology Guide 2026
euro-guideThe “16th European Biotechnology Science & Industry Guide 2026” – the handbook will present the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Latest NewsPharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.
Is "the hidden" publicly available?
OpinionThe Enlarged Board of Appeal (EBoA) of the European Patent Office will decide upon a question of high relevance for patents in the field biotechnology. The question to be decided concerns the interpretation of what has been “made available to the public”.